New Breakthrough: Cancer Drug CBL137 Shows Promise in Curing Hepatitis B!

A cancer drug that could cure Hepatitis B? It may sound unbelievable, but groundbreaking research from Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University has revealed that CBL137, an anticancer drug developed by Incuron, can effectively block Hepatitis B virus (HBV) infection in liver cells. Unlike current treatments that only suppress the virus, CBL137 targets cccDNA, preventing HBV from reproducing and reducing the production of key viral proteins like hepatitis B surface antigen.

This discovery could change everything for the 250 million people suffering from chronic Hepatitis B worldwide! Watch now to learn how this potential cure works, what researchers have discovered, and what comes next in the journey toward a functional Hepatitis B cure.

🔔 Subscribe now to stay updated on the latest medical breakthroughs!

📌 Sources & References:

https://biotech-insider.com/hbvs-abil...
https://www.mskcc.org/cancer-care/cli...

#HepatitisB #CBL137 #HepatitisBCure #MedicalBreakthrough #LiverHealth #HepatitisBResearch #Incuron #HealthNews #Science #CancerDrug #ClinicalTrials